$IGMS
IGM Biosciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022021592 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3
Revenue $331.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.66M $10.00M
YoY Change 26.6% 111.48%
% of Gross Profit
Research & Development $48.18M $34.20M
YoY Change 40.89% 116.03%
% of Gross Profit
Depreciation & Amortization $1.509M $1.100M
YoY Change 37.18% 450.0%
% of Gross Profit
Operating Expenses $60.84M $44.20M
YoY Change 37.66% 114.97%
Operating Profit -$60.51M -$44.20M
YoY Change 36.91% 114.97%
Interest Expense $2.475M $35.00K
YoY Change 6971.43%
% of Operating Profit
Other Income/Expense, Net $2.475M $35.00K
YoY Change 6971.43% -87.97%
Pretax Income -$60.51M -$44.16M
YoY Change 37.02% 117.88%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$58.04M -$44.16M
YoY Change 31.41% 117.88%
Net Earnings / Revenue -17533.84%
Basic Earnings Per Share -$1.32 -$1.32
Diluted Earnings Per Share -$1.32 -$1.321M
COMMON SHARES
Basic Shares Outstanding 44.03M 33.44M
Diluted Shares Outstanding 44.03M 33.44M

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $469.1M $259.5M
YoY Change 80.78% 44.01%
Cash & Equivalents $177.4M $165.6M
Short-Term Investments $291.7M $93.91M
Other Short-Term Assets $10.83M $8.899M
YoY Change 21.67% 102.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $480.0M $268.4M
YoY Change 78.82% 45.32%
LONG-TERM ASSETS
Property, Plant & Equipment $31.89M $28.23M
YoY Change 12.95% 6.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.115M
YoY Change
Other Assets $2.123M $910.0K
YoY Change 133.3% 87.24%
Total Long-Term Assets $60.97M $63.82M
YoY Change -4.46% 136.22%
TOTAL ASSETS
Total Short-Term Assets $480.0M $268.4M
Total Long-Term Assets $60.97M $63.82M
Total Assets $540.9M $332.2M
YoY Change 62.82% 56.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.731M $3.345M
YoY Change -18.36% 4.89%
Accrued Expenses $32.65M $13.93M
YoY Change 134.38% 86.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.48M $20.45M
YoY Change 117.52% 53.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $168.3M $26.20M
YoY Change 542.23% 154.39%
Total Long-Term Liabilities $168.3M $26.20M
YoY Change 542.23% 154.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.48M $20.45M
Total Long-Term Liabilities $168.3M $26.20M
Total Liabilities $212.8M $46.65M
YoY Change 356.05% 98.18%
SHAREHOLDERS EQUITY
Retained Earnings -$522.3M -$303.1M
YoY Change 72.32% 84.89%
Common Stock $850.8M $588.6M
YoY Change 44.54% 67.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $328.2M $285.6M
YoY Change
Total Liabilities & Shareholders Equity $540.9M $332.2M
YoY Change 62.82% 56.92%

Cashflow Statement

Concept 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$58.04M -$44.16M
YoY Change 31.41% 117.88%
Depreciation, Depletion And Amortization $1.509M $1.100M
YoY Change 37.18% 450.0%
Cash From Operating Activities -$40.41M -$34.82M
YoY Change 16.07% 130.88%
INVESTING ACTIVITIES
Capital Expenditures -$2.711M -$2.246M
YoY Change 20.7% -65.76%
Acquisitions
YoY Change
Other Investing Activities -$1.037M -$44.45M
YoY Change -97.67% -346.28%
Cash From Investing Activities -$3.748M -$46.70M
YoY Change -91.97% -506.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 297.0K 1.071M
YoY Change -72.27% -216.41%
NET CHANGE
Cash From Operating Activities -40.41M -34.82M
Cash From Investing Activities -3.748M -46.70M
Cash From Financing Activities 297.0K 1.071M
Net Change In Cash -43.86M -80.45M
YoY Change -45.47% 1679.76%
FREE CASH FLOW
Cash From Operating Activities -$40.41M -$34.82M
Capital Expenditures -$2.711M -$2.246M
Free Cash Flow -$37.70M -$32.57M
YoY Change 15.75% 282.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.43
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
362000
dei Entity Central Index Key
EntityCentralIndexKey
0001496323
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39045
dei Entity Registrant Name
EntityRegistrantName
IGM Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0349194
dei Entity Address Address Line1
EntityAddressAddressLine1
325 E. Middlefield Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Mountain View
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94043
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
965-7873
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
IGMS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177414000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133334000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
693000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
701000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
291725000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
96208000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10134000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10504000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
479966000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
240747000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31886000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28495000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26961000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27849000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2123000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1036000
CY2022Q3 us-gaap Assets
Assets
540936000
CY2021Q4 us-gaap Assets
Assets
298127000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2731000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5584000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32647000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18876000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4349000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3320000
CY2022Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
4757000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
0
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
44484000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27780000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23731000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25439000
CY2022Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
144546000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
212761000
CY2021Q4 us-gaap Liabilities
Liabilities
53219000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
850772000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
598373000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-775000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-66000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-522250000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-353724000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
328175000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
244908000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
540936000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
298127000
CY2022Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
331000
CY2021Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
0
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
697000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
0
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48179000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34196000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
134272000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87857000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12664000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10003000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38117000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26786000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
60843000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
44199000
us-gaap Operating Expenses
OperatingExpenses
172389000
us-gaap Operating Expenses
OperatingExpenses
114643000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60512000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-44199000
us-gaap Operating Income Loss
OperatingIncomeLoss
-171692000
us-gaap Operating Income Loss
OperatingIncomeLoss
-114643000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2475000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
35000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3289000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
121000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-123000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2475000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3166000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
121000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-58037000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-44164000
us-gaap Net Income Loss
NetIncomeLoss
-168526000
us-gaap Net Income Loss
NetIncomeLoss
-114522000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.43
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44034652
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44034652
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33438477
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33438477
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40634893
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40634893
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33380143
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33380143
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-58037000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-44164000
us-gaap Net Income Loss
NetIncomeLoss
-168526000
us-gaap Net Income Loss
NetIncomeLoss
-114522000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-313000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-709000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-27000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58350000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44163000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-169235000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-114549000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
244908000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
133000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-127000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11499000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-51894000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
204519000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
217987000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
477000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-269000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11286000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-58595000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
375411000
CY2022Q3 igms Stock Issued During Period Value Exercise Of Stock Options Net Of Shares Withheld For Taxes And Exercise Costs
StockIssuedDuringPeriodValueExerciseOfStockOptionsNetOfSharesWithheldForTaxesAndExerciseCosts
298000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-313000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10816000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-58037000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
328175000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
381815000
CY2021Q1 igms Stock Issued During Period Value Exercise Of Stock Options Net Of Shares Withheld For Taxes And Exercise Costs
StockIssuedDuringPeriodValueExerciseOfStockOptionsNetOfSharesWithheldForTaxesAndExerciseCosts
-53000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5504000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-31644000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
355610000
CY2021Q2 igms Stock Issued During Period Value Exercise Of Stock Options Net Of Shares Withheld For Taxes And Exercise Costs
StockIssuedDuringPeriodValueExerciseOfStockOptionsNetOfSharesWithheldForTaxesAndExerciseCosts
-438000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
405000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5609000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-38714000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
322456000
CY2021Q3 igms Stock Issued During Period Value Exercise Of Stock Options Net Of Shares Withheld For Taxes And Exercise Costs
StockIssuedDuringPeriodValueExerciseOfStockOptionsNetOfSharesWithheldForTaxesAndExerciseCosts
1071000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6212000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-44164000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
285576000
us-gaap Profit Loss
ProfitLoss
-168526000
us-gaap Profit Loss
ProfitLoss
-114522000
us-gaap Depreciation
Depreciation
4177000
us-gaap Depreciation
Depreciation
3181000
us-gaap Share Based Compensation
ShareBasedCompensation
33601000
us-gaap Share Based Compensation
ShareBasedCompensation
17325000
igms Purchase Net Discount Premium On Marketable Securities
PurchaseNetDiscountPremiumOnMarketableSecurities
-3433000
igms Purchase Net Discount Premium On Marketable Securities
PurchaseNetDiscountPremiumOnMarketableSecurities
251000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
726000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-486000
igms Non Cash Lease Expense
NonCashLeaseExpense
3203000
igms Non Cash Lease Expense
NonCashLeaseExpense
2365000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-759000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1693000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1087000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2570000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1280000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13432000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7277000
igms Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2994000
igms Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2208000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
149303000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
32005000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89682000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7511000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11481000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
381629000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
111108000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
182307000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
132813000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2997000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-206833000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13221000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1418000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
436000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1998000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
477000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
405000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
217987000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
218900000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
985000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
44072000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75476000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
134035000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
241080000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178107000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
165604000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177414000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165604000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
693000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178107000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165604000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2315000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19343000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
552000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
533000
CY2022Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
6000000.0
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
312500000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
113000000.0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-522300000
CY2022Q3 us-gaap Investments And Cash
InvestmentsAndCash
469100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Such management estimates include, but are not limited to, those related to revenue recognition, marketable securities, manufacturing accruals, accrued research and development expenses, stock-based compensation, operating lease right-of-use (ROU) assets and liabilities, income tax uncertainties and the valuation of deferred tax assets. The Company bases its estimates on its historical experience and also on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates. The most significant estimates and assumptions that management considers in the preparation of our financial statements relate to accrued research and development costs and revenue recognition.</span></p>
CY2022Q1 igms Number Of Voting Rights For Each Common Stock Held
NumberOfVotingRightsForEachCommonStockHeld
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company invests in money market funds, U.S. Treasury securities, corporate bonds, commercial paper, and U.S. government agency securities. The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers to the extent recorded on the balance sheets. The Company’s investment policy limits investments to high credit quality securities issued by the U.S. Government and its agencies, highly rated banks, and corporate issuers, subject to certain concentration limits and restrictions on maturities. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company’s early stages of clinical drug development; uncertainties related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; the Company’s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company’s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company’s ability to enroll patients in its ongoing and future clinical trials; the Company’s ability to successfully manufacture and supply its product candidates for clinical trials; the occurrence of any event or circumstance that could give rise to the termination of the Company’s collaborations with third parties; the Company’s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company’s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company’s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Quarterly Report on Form 10-Q.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s product candidates will require approvals from the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span></p>
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q4 igms Maximum Allowed Holding Percentage Of Shares After Exercise Of Warrants
MaximumAllowedHoldingPercentageOfSharesAfterExerciseOfWarrants
0.0999
CY2020Q4 igms Maximum Allowed Combined Voting Percentage Of Shares After Exercise Of Warrants
MaximumAllowedCombinedVotingPercentageOfSharesAfterExerciseOfWarrants
0.0999
CY2020Q4 igms Maximum Allowed Percentage Of Pre Funded Warrants To Exercise
MaximumAllowedPercentageOfPreFundedWarrantsToExercise
0.1999
CY2020Q4 igms Minimum Notice Term To Increase Or Decrease Holding Percentage Of Pre Funded Warrants
MinimumNoticeTermToIncreaseOrDecreaseHoldingPercentageOfPreFundedWarrants
P61D
CY2022Q3 igms Number Of Warrants Exercised
NumberOfWarrantsExercised
0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company’s results of operations or financial position as of September 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6342642
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3676468
CY2022Q3 igms Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
463067000
CY2022Q3 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2022Q3 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
783000
CY2022Q3 igms Cash And Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
462292000
CY2021Q4 igms Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
223396000
CY2021Q4 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 igms Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
66000
CY2021Q4 igms Cash And Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
223330000
CY2022Q3 igms Number Of Financial Instruments Classified As Level Three
NumberOfFinancialInstrumentsClassifiedAsLevelThree
0
CY2021Q4 igms Number Of Financial Instruments Classified As Level Three
NumberOfFinancialInstrumentsClassifiedAsLevelThree
0
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
17000
CY2022Q3 igms Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
21332000
CY2021Q4 igms Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
10829000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1719000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1019000
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8915000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6748000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
681000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
280000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32647000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18876000
igms Deferred Revenue Addition
DeferredRevenueAddition
150000000
igms Deferred Revenue Deduction
DeferredRevenueDeduction
-697000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
149303000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2022Q3 igms Contract With Customer Assets
ContractWithCustomerAssets
0
CY2021Q3 igms Contract With Customer Assets
ContractWithCustomerAssets
0
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock (excluding non-voting common stock) is entitled to one vote.
CY2022Q3 igms Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
5715344
CY2021Q4 igms Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
3764001
CY2022Q3 igms Restricted Stock Units
RestrictedStockUnits
594511
CY2021Q4 igms Restricted Stock Units
RestrictedStockUnits
358535
CY2022Q3 igms Stock Options And Restricted Stock Units Future Issuance
StockOptionsAndRestrictedStockUnitsFutureIssuance
1464844
CY2021Q4 igms Stock Options And Restricted Stock Units Future Issuance
StockOptionsAndRestrictedStockUnitsFutureIssuance
2618117
CY2022Q3 igms Employee Stock Purchase Plan Number Of Shares Available For Grant
EmployeeStockPurchasePlanNumberOfSharesAvailableForGrant
1141642
CY2021Q4 igms Employee Stock Purchase Plan Number Of Shares Available For Grant
EmployeeStockPurchasePlanNumberOfSharesAvailableForGrant
855206
CY2022Q3 igms Pre Funded Warrants
PreFundedWarrants
1334332
CY2021Q4 igms Pre Funded Warrants
PreFundedWarrants
1334332
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10250673
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8930191
CY2022Q3 us-gaap Payments For Rent
PaymentsForRent
35018000

Files In Submission

Name View Source Status
igms-20220930_cal.xml Edgar Link unprocessable
0000950170-22-021592-index-headers.html Edgar Link pending
0000950170-22-021592-index.html Edgar Link pending
0000950170-22-021592.txt Edgar Link pending
0000950170-22-021592-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
igms-20220930.htm Edgar Link pending
igms-20220930.xsd Edgar Link pending
igms-ex31_1.htm Edgar Link pending
igms-ex31_2.htm Edgar Link pending
igms-ex32_1.htm Edgar Link pending
igms-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
igms-20220930_def.xml Edgar Link unprocessable
igms-20220930_pre.xml Edgar Link unprocessable
igms-20220930_lab.xml Edgar Link unprocessable
igms-20220930_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending